Centrophenoxine Research Overview (also known as Meclofenoxate, Lucidril, ANP 235)
Centrophenoxine, also called meclofenoxate, is a synthetic nootropic compound formed from dimethylaminoethanol (DMAE) and p-chlorophenoxyacetic acid (pCPA). It has been investigated for effects on cholinergic signaling, age-related cognitive decline, cellular waste products such as lipofuscin, and oxidative stress, although modern evidence for meaningful cognitive or longevity benefits in healthy adults remains limited.
What Is Centrophenoxine?
Centrophenoxine is a synthetic ester of dimethylaminoethanol, usually abbreviated DMAE, and p-chlorophenoxyacetic acid, abbreviated pCPA. It was developed in France in 1959 and later marketed in several countries under names including meclofenoxate, Lucidril, and ANP 235. The compound is generally discussed as a cholinergic-supporting nootropic because the DMAE portion is related chemically to choline and may contribute to acetylcholine-related effects. pCPA is thought to alter the compound's physicochemical properties and distribution, while hydrolysis can release DMAE and p-chlorophenoxyacetic acid derivatives.
Centrophenoxine was developed partly to improve delivery of DMAE to the central nervous system. DMAE itself is a small, water-soluble amino alcohol, but its brain availability and pharmacological significance are uncertain. Centrophenoxine is more lipophilic than DMAE and has historically been described as crossing the blood-brain barrier more effectively than unmodified DMAE. This description should not be interpreted as proof of high brain concentrations or a predictable increase in acetylcholine in humans. Much of the supporting literature is old, involves animal or cell models, or concerns patients with cognitive impairment rather than healthy adults. It is not approved as a cognitive enhancer or longevity treatment in every jurisdiction.
The compound is commonly encountered as an oral tablet or capsule. Historical medical use has included investigation in senile dementia, cerebrovascular disorders, and other conditions associated with cognitive impairment. Contemporary interest is largely driven by nootropic communities and by mechanistic theories concerning cholinergic transmission, membrane phospholipid metabolism, oxidative damage, and the clearance or reduction of lipofuscin. These theories are biologically plausible in some respects, but evidence that oral centrophenoxine produces durable improvements in memory, slows human aging, or removes lipofuscin from human brain tissue is not established.
Research Indications
Cognitive Performance
Age-related cognitive symptoms
Older clinical literature evaluated meclofenoxate for cognitive and functional symptoms associated with aging and organic brain syndromes. Study methods and reporting standards vary substantially.
Attention and mental fatigue
Centrophenoxine is used in nootropic communities for subjective alertness and reduced mental fatigue, but controlled evidence in healthy adults remains limited.
Cholinergic Activity
Acetylcholine precursor rationale
Meclofenoxate is an ester related to dimethylaminoethanol and p-chlorophenoxyacetic acid; proposed nootropic effects have often been discussed in relation to cholinergic signaling.
Memory-related mechanisms
Preclinical findings suggest effects on neuronal membrane processes and neurotransmitter systems, though these mechanisms do not establish clinical efficacy.
Cellular Aging Research
Lipofuscin research
Animal and cell studies have examined whether centrophenoxine influences lipofuscin accumulation and oxidative-stress-related markers. Human anti-aging benefit has not been established.
Mitochondrial and membrane hypotheses
Laboratory hypotheses include support of membrane turnover and cellular resilience; these remain mechanistic observations rather than validated therapeutic indications.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Initial tolerance assessment | 250 mg | Once daily | Oral |
| Cognitive research use | 250–500 mg | 1–2 times daily | Oral |
| Older clinical literature | 500–1,000 mg/day | Divided doses | Oral |
| Short research trial | Up to 1,500 mg/day | Divided doses | Oral |
Timing
Research users commonly take centrophenoxine earlier in the day, with food if gastrointestinal discomfort occurs. Avoid late-day dosing when alertness, restlessness, or insomnia is a concern.
Peptide Interactions
May provide complementary cholinergic support, though direct combination trials are lacking. Introduce one compound at a time to assess tolerability.
Combined cholinergic approaches may increase headache, nausea, muscle tension, or insomnia in sensitive individuals.
Potentially additive alerting effects may increase jitteriness, anxiety, palpitations, or sleep disruption.
Donepezil, rivastigmine, and similar medicines should only be combined under clinician supervision because of overlapping cholinergic effects.
These medicines may oppose cholinergic signaling conceptually; do not alter prescribed medication regimens without professional guidance.
Limited direct interaction data exist, but concurrent use with amphetamine- or methylphenidate-based therapy may worsen activation or insomnia.
Reported Research Timeline
01First dose to 3 days (reported in cited studies): some users report mild alertness or no noticeable acute effect; headache, nausea, or restlessness may occur in sensitive individuals.
02Days 4–7 (reported in cited studies): tolerability is usually easier to assess. Sleep quality, anxiety, gastrointestinal effects, and daytime focus are useful variables to track.
03Weeks 2–3 (reported in cited studies): any subjective changes in mental fatigue, concentration, or motivation are generally evaluated over repeated daily use rather than a single dose.
04Weeks 4–6 (reported in cited studies): review whether there is a consistent, measurable benefit. Evidence does not support assuming progressive cognitive improvement.
05After 6–8 weeks (reported in cited studies): reassess continued use with a clinician, especially if taking prescription cognitive, psychiatric, cardiovascular, or stimulant medications.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Human safety data for long-term, nonmedical use are limited; use the lowest practical exposure and avoid escalating dose without a clear reason.
Potential adverse effects reported with cholinergic or activating compounds include headache, nausea, gastrointestinal upset, irritability, dizziness, and insomnia.
Avoid use during pregnancy or breastfeeding because adequate safety data are unavailable.
Use caution with a history of anxiety, panic symptoms, bipolar-spectrum illness, insomnia, seizure disorders, or clinically significant cardiac rhythm symptoms.
Discuss use with a pharmacist or clinician if taking cholinergic drugs, stimulants, anticholinergics, psychiatric medicines, or multiple supplements.
Seek Medical Attention If:
You develop chest pain, fainting, severe palpitations, shortness of breath, or a sustained rapid heartbeat.
You experience severe agitation, confusion, mania-like symptoms, hallucinations, or a seizure.
You have signs of a serious allergic reaction, including facial or throat swelling, hives, wheezing, or difficulty breathing.
Persistent vomiting, severe headache, or marked insomnia continues after stopping the product.
Quality Indicators
Verified Marker
Batch-specific certificate of analysis
Select products with a recent lot-specific COA identifying meclofenoxate or centrophenoxine, lot number, assay method, and result.
Verified Marker
HPLC or equivalent identity and purity testing
A credible report should state an analytical method such as HPLC and provide a quantified purity result rather than a generic claim of laboratory testing.
Verified Marker
Heavy-metal and microbial screening
Prefer independent testing for lead, arsenic, cadmium, mercury, and relevant microbial contaminants, particularly for bulk powders and capsules.
Acceptable Range
Accurate capsule or scoop labeling
The label should clearly specify milligrams of active compound per capsule or serving, excipients, suggested storage, and the manufacturer or responsible distributor.
Quality Concern
Unverifiable purity claims or absent lot data
Avoid products that provide only a marketing-grade COA, omit lot numbers, do not identify the analyte tested, or make implausible pharmaceutical-grade claims without documentation.
Research Citations
- Piracetam and other structurally related nootropics
Gouliaev, A. H., Senning, A., et al., 1994, Brain Research Reviews - Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders
Malykh, A. G., Sadaie, M. R., et al., 2010, Drugs - Piracetam: a review of pharmacological properties and clinical uses
Winblad, B., et al., 2005, CNS Drug Reviews - Clinical efficacy of piracetam in cognitive impairment: a meta-analysis
Waegemans, T., Wilsher, C. R., Danniau, A., et al., 2002, Dementia and Geriatric Cognitive Disorders
Research Focus
acetylcholine, lipofuscin removal, antioxidant, cognitive enhancement, longevity, DMAE
Frequently Asked Questions
What should researchers watch for with Centrophenoxine?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Centrophenoxine?
First dose to 3 days (reported in cited studies): some users report mild alertness or no noticeable acute effect; headache, nausea, or restlessness may occur in sensitive individuals.
How is Centrophenoxine typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →